Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

RNAC

+ Watchlist+ Portfolio

Cartesian Therapeutics, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$6.12
52-Week Range
$5.60 – $11.00
Market Cap
$192.17M
P/E (TTM)
—
EPS (TTM)
-4.78
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
-19.23%
Gross Margin
0.00%
Operating Margin
-10009.17%
Profit Margin
0.00%
Current Ratio
8.38
Debt/Equity
—
Total Debt
$60.34M
Free Cash Flow
$-58.12M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$129.53M

Market Snapshot

About

Cartesian Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel cell therapies for autoimmune diseases. The company utilizes its proprietary RNA chimeric antigen receptor (RNA CAR) technology to create off-the-shelf cellular immunotherapies. Cartesian is focused on B cell-mediated autoimmune conditions with significant unmet medical needs.